Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:
加利福尼亚州伯克利，2024年11月20日（GLOBE NEWSWIRE）——临床阶段领先的CRISPR基因组编辑生物制药公司Caribou Biosciences, Inc.（纳斯达克股票代码：CRBU）今天宣布，Caribou总裁兼首席执行官雷切尔·豪尔维茨博士将参加以下投资者会议：
-
Citi's 2024 Global Healthcare Conference, Miami, FL
December 3, 2024, panel at 2:30 PM EST
Panel title: Cell therapies in autoimmune disorders
Webcast
- 花旗2024年全球医疗保健会议，佛罗里达州迈阿密
2024 年 12 月 3 日，美国东部标准时间下午 2:30 的小组讨论
小组讨论标题：自身免疫性疾病的细胞疗法
网络直播
-
7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FL
December 4, 2024, fireside chat at 10:25 AM EST
Webcast
- 第七届年度 Evercore ISI HealthConx 会议，佛罗里达州科勒尔盖布尔斯
2024 年 12 月 4 日，美国东部标准时间上午 10:25 的炉边谈话
网络直播
For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
欲了解更多信息，请访问Caribou网站上的活动页面。网络直播将在活动结束后的30天内在Caribou网站上播出。
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
关于 Caribou 的新型下一代 CRISPR 平台
CRISPR 基因组编辑使用易于设计的模块化生物学工具对活细胞进行 DNA 更改。2 类 CRISPR 系统有两个基本组成部分：切割 DNA 的核酸酶蛋白和引导核酸酶产生位点特异性双链断裂、导致目标基因组位点编辑的 RNA 分子。CRISPR系统能够编辑意想不到的基因组位点，即脱靶编辑，这可能会对细胞功能和表型造成有害影响。为了应对这一挑战，Caribou开发了CRISPR混合RNA-DNA指南（chrDNA；发音为 “chardonnays”），与全RNA指南相比，它指导的基因组编辑要精确得多。Caribou正在利用其chrDNA技术的力量进行高效的多次编辑，开发经过CRISPR编辑的疗法。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .
关于 Caribou Biosciences, Inc.
Caribou Biosciences是一家临床阶段的CRISPR基因组编辑生物制药公司，致力于为患有毁灭性疾病的患者开发变革性疗法。该公司的基因组编辑平台，包括其Cas12a chrDNA技术，能够以卓越的精度开发具有潜在改善疾病活性的细胞疗法。Caribou正在推进其CAR-T平台的现成细胞疗法产品线，为血液系统恶性肿瘤和自身免疫性疾病患者提供现成的治疗方法。关注我们 @CaribouBio 并访问。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou 生物科学公司联系方式：
投资者：
艾米·菲格罗亚，特许金融分析师
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒体：
佩吉·沃瓦尔德，博士
media@cariboubio.com
